Journal

503A vs 503B: A Patient Verification Checklist

Explain registration is not FDA approval

The distinction in one paragraph

Section 503A covers traditional pharmacy compounding: a state-licensed pharmacy preparing a medicine for an identified individual patient pursuant to a prescription. Oversight is primarily the state board of pharmacy. CGMP requirements do not apply, and there is no requirement to register with the FDA as an outsourcing facility.

Section 503B created outsourcing facilities: entities that register with the FDA, may compound larger batches without patient-specific prescriptions, must comply with current good manufacturing practice, are inspected by the FDA on a risk-based schedule, and must report adverse events to the agency.

The framework was created in 2013 following a fungal meningitis outbreak traced to contaminated compounded injections that killed dozens of people. The distinction exists because of that.

Why it matters more in 2026 than it did

The FDA's April 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list targets outsourcing-facility compounding from bulk substances specifically. It does not address 503A patient-specific compounding, which operates under different conditions and was never designed for industrial volume.

So "which registration fills my prescription" has gone from a technical question to a question about whether your supply route is the one under active regulatory proposal.

The checklist

1. Which specific pharmacy or facility fills my prescription? The name, not "our network."
2. Is it 503A or 503B? A company may use both for different products.
3. In which state is it licensed, and can I look it up? State boards publish licensee databases.
4. If 503B is claimed, is it on the FDA's registered outsourcing facility list?
5. What is the exact salt form and concentration? Semaglutide sodium and acetate are not the semaglutide base in approved products.
6. Single-dose or multi-dose vial? Multi-dose means you measure each dose yourself, which is the most common source of reported dosing errors.
7. Will you provide a certificate of analysis?
8. Has the pharmacy received an FDA warning letter or state board action?

A provider that answers all eight in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer whether it intended to or not.

What FDA registration actually establishes

Less than the summaries imply. The agency's own position is that registration means only that it has received the required information — not that the facility is making FDA-approved drugs, and not that it is in compliance with CGMP or the other conditions of section 503B.

CGMP compliance is a legal requirement. Registration is not evidence that a given facility meets it. The useful questions are whether it has been inspected, what the inspection found, and whether a warning letter followed.

Where to check, specifically

• FDA outsourcing facility register — confirms current 503B registration and links a searchable product report database.
• NABP directory — routes you to the state board that licenses the pharmacy, and to its licensee and nonresident registers.
• FSMB directory — routes you to the medical board that licenses the prescriber.
• FDA warning letters and recall notices — public, searchable by facility name.

Each is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.

Why the distinction became commercially decisive in 2026

The FDA proposal to exclude tirzepatide from the 503B bulks list targets outsourcing-facility compounding from bulk substances. Patient-specific 503A compounding operates under separate conditions and is not addressed.

So "which registration fills my prescription" has moved from a technical detail to a question about whether your supply route is the one under active regulatory review. It is the single most useful question a patient on a compounded product can ask right now.

What neither category gives you

An FDA-approved medicine. No compounded product is approved, whichever class made it, and no licence, registration or accreditation changes that.

If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.

Questions readers actually ask